Meyer, A. ., Horton, D. ., Neugebauer, N. ., Wooters, T. ., , Dwoskin, L. ., & Bardo, M. . (2011). Tetrabenazine inhibition of monoamine uptake and methamphetamine behavioral effects: locomotor activity, drug discrimination and self-administration. Neuropharmacology, 61(4), 849-56. https://doi.org/10.1016/j.neuropharm.2011.05.033

Horton, D. ., Siripurapu, K. ., Norrholm, S. ., Culver, J. ., Hojahmat, M. ., Beckmann, J. ., … Dwoskin, L. . (2011). meso-Transdiene analogs inhibit vesicular monoamine transporter-2 function and methamphetamine-evoked dopamine release. The Journal of Pharmacology and Experimental Therapeutics, 336(3), 940-51. https://doi.org/10.1124/jpet.110.175117

Beckmann, J. ., Siripurapu, K. ., , Horton, D. ., Denehy, E. ., Vartak, A. ., … Bardo, M. . (2010). The novel pyrrolidine nor-lobelane analog UKCP-110 cis-2,5-di-(2-phenethyl)-pyrrolidine hydrochloride inhibits VMAT2 function, methamphetamine-evoked dopamine release, and methamphetamine self-administration in rats. The Journal of Pharmacology and Experimental Therapeutics, 335(3), 841-51. https://doi.org/10.1124/jpet.110.172742

Beckmann, J. ., Meyer, A. ., Pivavarchyk, M. ., Horton, D. ., Zheng, G. ., Smith, A. ., … Dwoskin, L. . (2015). r-bPiDI, an α6β2* Nicotinic Receptor Antagonist, Decreases Nicotine-Evoked Dopamine Release and Nicotine Reinforcement. Neurochemical Research, 40(10), 2121-30. https://doi.org/10.1007/s11064-015-1680-4